<p>Comparison of sorafenib with other regimens for HCC patients in terms of time to progression (TTP).</p
Objectives: Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored whether any speci...
Sorafenib is a standard treatment for advanced hepatocellular carcinoma (HCC) (Barcelona Clinic Live...
hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated...
<p>Comparison of sorafenib with other regimens for HCC patients in terms of overall survival (OS).</...
<p>Comparison of sorafenib with other regimens for HCC patients in terms of overall response rate (O...
<p>The comparison between chemotherapy regimens in overall survival (AC regimen vs. FAC/FEC regimen ...
Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also...
<p>Comparison of overall and HCC-specific survival between patients with and patients without EHPC b...
<p>Progression-free and overall survival in sarcopenic (dot line) and non-sarcopenic (solid line) HC...
<p>The result of meta-analysis for TTP between TACE alone group and sorafenib combined with TACE gro...
[Background and Aims] The combination therapy of transarterial chemoembolization (TACE) plus sorafen...
<p>Comparison of overall and HCC-specific survival between patients with EHPC and patients without E...
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hep...
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hep...
Background: Regorafenib has been shown to improve clinical outcomes compared to placebo, becoming a ...
Objectives: Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored whether any speci...
Sorafenib is a standard treatment for advanced hepatocellular carcinoma (HCC) (Barcelona Clinic Live...
hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated...
<p>Comparison of sorafenib with other regimens for HCC patients in terms of overall survival (OS).</...
<p>Comparison of sorafenib with other regimens for HCC patients in terms of overall response rate (O...
<p>The comparison between chemotherapy regimens in overall survival (AC regimen vs. FAC/FEC regimen ...
Treatment outcomes of sorafenib therapy may greatly vary depending not only on tumor spread but also...
<p>Comparison of overall and HCC-specific survival between patients with and patients without EHPC b...
<p>Progression-free and overall survival in sarcopenic (dot line) and non-sarcopenic (solid line) HC...
<p>The result of meta-analysis for TTP between TACE alone group and sorafenib combined with TACE gro...
[Background and Aims] The combination therapy of transarterial chemoembolization (TACE) plus sorafen...
<p>Comparison of overall and HCC-specific survival between patients with EHPC and patients without E...
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hep...
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hep...
Background: Regorafenib has been shown to improve clinical outcomes compared to placebo, becoming a ...
Objectives: Hepatocellular carcinoma (HCC) is a heterogeneous disease. We explored whether any speci...
Sorafenib is a standard treatment for advanced hepatocellular carcinoma (HCC) (Barcelona Clinic Live...
hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated...
DOI
Add to ORKG